论文部分内容阅读
目的探讨拉米夫定耐药后慢性乙型肝炎患者采用α2b干扰素或α2b干扰素加α1胸腺肽进行后续抗病毒的疗效。方法共66例拉米夫定耐药患者,分治疗组A、治疗组B和对照组。治疗组A26例,单用α2b干扰素治疗1个月后停用拉米夫定,然后继续单用α2b干扰素治疗5个月;治疗组B10例,α2b干扰素和α1胸腺肽联合治疗1个月后停用拉米夫定,然后继续两药联合治疗5个月;对照组30例,直接停用拉米夫定,不用其他任何抗病毒药。定期进行血清肝功和病毒学指标检测。结果治疗组A和治疗组B的HBVDNA阴转率和HBeAg/HBeAb转换率均明显高于对照组。结论慢性乙型肝炎患者拉米夫定耐药后采用α2b干扰素或α2b干扰素加α1胸腺肽进行后续抗病毒治疗可能是有益的。
Objective To investigate the efficacy of subsequent antiviral therapy with α2b interferon or α2b interferon plus α1 thymosin in patients with chronic hepatitis B after lamivudine resistance. Methods A total of 66 cases of lamivudine resistant patients, treatment group A, treatment group B and control group. The treatment group A26 cases, α2b interferon treatment alone after 1 month lamivudine withdrawal, and then continue with α2b interferon alone for 5 months; treatment group B10, α2b interferon and α1 thymosin combination therapy for 1 month After stopping the use of lamivudine, and then continue the two-drug combination therapy for 5 months; control group of 30 patients, direct use of lamivudine, without any other antiviral drugs. Regular serum liver function and virological detection. Results The conversion rate of HBVDNA and HBeAg / HBeAb in treatment group A and treatment group B were significantly higher than those in control group. Conclusion It may be beneficial to use anti-HIV treatment with α2b interferon or α2b interferon plus α1 thymosin after lamivudine resistance in patients with chronic hepatitis B.